Clinical trials: Resolution
Cataract Surgery
Efficacy and Safety of Bromfenac Ophthalmic Solution
This is a safety and efficacy study of bromfenac ophthalmic solution
- Trial name
- NCT00585975
- Testing
- bromfenac ophthalmic solution
- Where
- United States
- Volunteers
- 568 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Pharyngitis, Tonsillitis
PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients
This Post-Authorization Safety Study (PASS) is intended to fulfill a regulatory post-marketing requirement to provide data regarding visual abilities in children taking azithromycin (immediate-release formulation) for acute…
- Trial name
- NCT01919996
- Testing
- Azithromycin
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- Pfizer
Primary Open Angle Glaucoma, Ocular Hypertension
Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)
Aim: To demonstrate the non-inferiority of the PRO-122 ophthalmic solution manufactured by Laboratorios Sophia S.A. de C.V. versus Krytantek Ofteno® ophthalmic solution like hypotensive therapy in subjects with primary open angle…
- Trial name
- CONFORTK (NCT03257813)
- Testing
- PRO-122, Krytantek Ofteno®
- Volunteers
- 60 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye Disease
A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.
Primary objective To evaluate the efficacy of 5 μg/mL and 10 μg/mL concentrations of the new formulation of rhNGF ophthalmic solution versus vehicle, in order to demonstrate superiority of at least 1 of the concentrations over…
- Trial name
- REDUCO (NCT06244316)
- Testing
- rhNGF 5 μg/mL, rhNGF 10 μg/mL
- Where
- 14 sites in United States, Italy
- Volunteers
- 317 people
- Sponsor
- Dompé Farmaceutici S.p.A
Healthy
Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers
The purpose of this study is to look at the pharmacokinetics of a new formulation of deferiprone (deferiprone delayed release tablets) under fed and fasting conditions.
- Trial name
- NCT02442310
- Testing
- Deferiprone delayed release tablet formulation, Deferiprone oral solution
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- ApoPharma
Anesthesia, Local
A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution
A Phase 3, randomized, placebo-controlled, double-masked, parallel study in healthy subjects. It is designed to evaluate the ocular safety of a single topical ocular administration of AG-920 sterile topical ophthalmic solution…
- Trial name
- NCT05501860
- Testing
- AG-920
- Where
- 2 sites in United States
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- American Genomics, LLC
Androgenetic Alopecia
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
Open label study to assess safety, tolerability, and efficacy of ATI-50002 in male and female subjects with androgenetic alopecia.
- Trial name
- NCT03495817
- Testing
- ATI-50002
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Aclaris Therapeutics, Inc.
Acute Otitis Media
Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients
The purpose of this study is to determine if a combination of an antibiotic plus a corticosteroid is safe and effective in treating middle ear infections in children with ear tubes.
- Trial name
- NCT01404611
- Testing
- DF289, DF277, DF289 plus DF277
- Where
- Spain
- Volunteers
- 331 people
- Sponsor
- Salvat
HIV Infections, Proteinuria
Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria
The study is designed to evaluate the proportion of patients with tenofovir induced proteinuria that will resolve their proteinuria when the tenofovir containing nucleoside/nucleotide backbone is switched to a raltegravir…
- Trial name
- RALPIR (NCT01044771)
- Testing
- change from tenofovir to raltegravir
- Volunteers
- 20 people
- Sponsor
- Metropolis Medical
Dim Light Vision Disturbances
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances
The objectives of this study are: To evaluate the efficacy of Nyxol to improve mesopic low contrast visual acuity (mLCVA) in subjects with Dim Light Vision Disturbances (DLD) To evaluate efficacy of Nyxol to improve visual…
- Trial name
- NCT04638660
- Testing
- Phentolamine Ophthalmic Solution 0.75%
- Where
- 17 sites in United States
- Volunteers
- 144 people
- Sponsor
- Opus Genetics, Inc
Healthy
A Study of Galcanezumab in Healthy Participants.
The main purpose of this study is to evaluate how much galcanezumab gets into the body after it is given as an injection just under the skin by two different devices.
- Trial name
- NCT02836613
- Testing
- Galcanezumab
- Where
- 3 sites in United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Asthma
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma
The primary objective of this trial is to evaluate the safety and efficacy of two doses of tiotropium inhalation solution delivered via the Respimat® inhaler once daily in the afternoon in patients (1 to 5 years old) with…
- Trial name
- NCT01634113
- Testing
- tiotropium-bromide
- Where
- 33 sites in United States, Belgium and 9 more
- Volunteers
- 102 people
- Sponsor
- Boehringer Ingelheim
Ocular Hypertension, Open Angle Glaucoma
Study of AR-13324 in Patients With Elevated Intraocular Pressure
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days.
- Trial name
- NCT01528787
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 11 sites in United States
- Volunteers
- 85 people
- Sponsor
- Aerie Pharmaceuticals
Dry Eye Syndrome, Dry Eye
Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye
Thymosin Beta 4 (Tβ4) is a synthetic copy of the naturally-occurring 43-amino acid peptide that is found in a variety of tissues. Tβ4 promotes/accelerates wound repair in dermal, ocular, and cardiac animal models.
- Trial name
- NCT01387347
- Testing
- Thymosin beta 4
- Volunteers
- 72 people
- Sponsor
- ReGenTree, LLC
Dry Eye
An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye
The primary objective of this study was to assess the efficacy and safety of rhNGF when administered as eye drops to patients with dry eye The secondary objectives of this study were: To assess change from baseline in Symptom…
- Trial name
- NCT03019627
- Testing
- NGF, Vehicle
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Dompé Farmaceutici S.p.A
Tinea Pedis
Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete's Foot
The purpose of this study is to determine the fungicidal efficacy of nitric oxide releasing solution footbath and it's effect on the clinical signs and symptoms associated with Tinea Pedis
- Trial name
- NCT02871011
- Testing
- Nitric Oxide, Water
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Nitric Solutions Inc.
Healthy
This Study Tests BI 1467335 in Healthy Male Volunteers. The Study Tests How Different Doses of BI 1467335 Are Taken up and Handled by the Body
Primary objective mass balance, excretion pathways and metabolism following a single oral dose of [14C]BI 1467335 given to healthy male subjects (a selected number of subjects will be treated with [14C]BI 1467335 after a…
- Trial name
- NCT03382509
- Testing
- [14C]BI 1467335, BI 1467335
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Constrictive Bronchiolitis, Bronchiolitis Obliterans
Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome
Background: Bronchiolitis obliterans or bronchiolitis obliterans syndrome is a lung disorder that occurs as a complication of either lung transplantation or bone marrow/blood stem cell transplantation.
- Conditions
- Constrictive Bronchiolitis, Bronchiolitis Obliterans, Graft vs Host Disease, Bronchiolitis, Exudative
- Trial name
- NCT01287078
- Testing
- Cyclosporine Inhalation Solution
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Dry Eye
Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)
SDP-4-CS201, is a Phase 2, multi-center, double-masked, randomized, vehicle-controlled, dose-response, parallel-group study designed to evaluate the ocular and systemic safety and efficacy of SDP-4 ophthalmic solution in subjects…
- Trial name
- SDP-4-CS201 (NCT03889886)
- Testing
- SDP-4 Ophthalmic Solution (0.1%), SDP-4 Ophthalmic Solution (1.0%), SDP-4 Ophthalmic Solution (3.0%)
- Where
- 26 sites in United States
- Volunteers
- 305 people
- Sponsor
- Silk Technologies, Ltd.
Bacterial Conjunctivitis
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
The purpose of this study is to evaluate the clinical and microbial efficacy and safety of AzaSite compared to tobramycin for bacterial conjunctivitis.
- Trial name
- NCT00105469
- Testing
- AzaSite, Tobramycin
- Where
- 26 sites in United States
- Volunteers
- 743 people
- Sponsor
- Merck Sharp & Dohme LLC